Tag: NTAGI

  • NTAGI to discuss India’s first mRNA COVID vaccine data

    By Express News Service

    NEW DELHI: The National Technical Advisory Group on Immunisation’s (NTAGI) Covid working group is expected to soon discuss data related to India’s first mRNA vaccine against Covid, an official source said Monday.

    The country’s first homegrown mRNA Covid-19 vaccine developed at Pune’s Gennova Biopharmaceuticals recently received emergency use for the age group 18 years and above from the Drugs Controller General of India (DCGI).

    The NTAGI Covid working group is also said to discuss Biological E’s Corbevax booster dose for Covishield and Covaxin beneficiaries.

    The Subject Expert Committee (SEC) under India’s drug regulator is said to be satisfied with the data submitted by the Pune-based firm in its meeting last week.

    Gennova Biopharmaceuticals submitted the data in April. They were asked for additional information, which they provided in May. 

    The pharma company said they aim to produce around 4-5 million doses per month, which can be quickly doubled as soon as they get a go-ahead from the government.

    The company has 7 million doses approved and released by the Central Drug Laboratory in Kasauli.

    Apart from India, Gennova aims to provide access to low-and middle-income countries worldwide to blunt the spread of pandemics.

    The mRNA vaccine produced by Gennova Biopharmaceuticals Ltd will be sold under the brand name GEMCOVAC-19.

    The company is also discussing the pricing of the vaccine with the government.

    GEMCOVAC-19 is a thermostable vaccine and can be stored between temperatures of 2 to 8 C, which makes it favourable for deployment in India and other developing nations, as it can be transported to the most remote parts easily.

    In contrast, mRNA vaccines made by Pfizer-BioNTech and Moderna need to be stored at sub-zero temperatures, which remains a challenge in lower and middle-income countries, officials said.

    mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms, Gennova claimed. Its technology allows quick tweak of the vaccine for any existing or emerging virus variants.

  • BA.2.75, other Omicron sub-variants need to be monitored as they can trigger reinfections: Dr N K Arora

    By Express News Service

    India has not reported a new Covid variant of concern in the past six months. However, there is a need to closely monitor the transmission dynamics and virulence of some Omicron sub-lineages as many of these can trigger reinfections, according to Dr N K Arora, chairperson of the Covid working group, National Technical Advisory Group on Immunisation (NTAGI).

    “Across the country, Omicron’s BA.2 and its sub-lineages, including BA.2.38, are the dominant strains. Recently, BA.4 and BA.5 were found in some 10 per cent of samples. BA.2.75 was also detected. Many of them can trigger reinfections, but they have not been associated with severe disease. Overall, the sub-lineages are evolving and their dynamics need to be closely monitored,” Dr Arora was quoted as saying in a TOI report.

    On Thursday, India reported 18,930 new COVID cases in the last 24 hours, according to the Ministry of Health and Family Welfare.  

    ALSO READ | Omicron sub-variant BA.2.75 detected in India, Centre says closely following its clinical behaviour

    According to Dr Arora, the ongoing spike is part of the third wave, not a fourth. “There is another dimension to this. Cases are mostly limited to metros and big cities with high population density. Recently, smaller towns also started to see upticks. Population density, increased travel and gatherings, along with poor adherence to Covid protocols, are factors linked to surges. Important thing is, most patients these days are vaccinated and go on to have common-cold or mild influenza-like illnesses,” he said.

    Meanwhile, WHO Director-General Tedros Adhanom Ghebreyesus expressed concern over sub-lineage BA.2.75 of the Omicron variant which has been detected in India and other countries. “The World Health Organisation is tracking this,” he said.

    WHO Chief Scientist Soumya Swaminathan said in a video posted on Twitter that there has been an emergence of a sub-variant that is being called the BA.2.75. It was first reported from India and then from about 10 other countries.

    ALSO READ | Active Covid cases in India rise to 1,19,457; New Omicron sub-variant BA.2.75 detected in country

    She said: “There are still limited sequences available of the sub-variant to analyse, but this sub-variant seems to have a few mutations on the receptor-binding domain of the spike protein. So obviously, that’s a key part of the virus that attaches itself to the human receptor. So we have to watch that. It’s still too early to know if this sub-variant has properties of additional immune evasion or indeed of being more clinically severe. We don’t know that. So we have to wait and see.

    She further said WHO is tracking it and the WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) is constantly looking at the data from around the world. “And at any time if there is an emergence of a virus that looks very different from a previous one, enough to be called a separate variant of concern, then the committee will do that.”

    The WHO weekly epidemiological update on COVID-19, released July 6, said that globally, the number of new weekly cases increased for the fourth consecutive week after a declining trend since the last peak in March 2022.

    During the week of June 27 to July 3, over 4.6 million cases were reported, a figure similar to that of the previous week. The number of new weekly deaths declined by 12% as compared to the previous week, with over 8100 fatalities reported. As of July 3, 2022, over 546 million confirmed COVID19 cases and over 6.3 million deaths had been reported globally.

    ALSO READ | Omicron sub-variants are better at evading vaccines, antibody treatments: Study

    The COVID update said that among Omicron lineages, the proportions of BA.5 and BA.4 continue to increase. BA.5 has been detected in 83 countries. Although BA.4, which has been detected in 73 countries, is also rising globally, the rate of increase is not as high as that of BA.5.

    The South-East Asia Region has been reporting an increasing trend in cases since early June, with over 157,000 new cases reported, a 20% increase as compared to the previous week.

    Five of 10 countries (50 per cent) for which data are available showed increases in the number of new cases of 20% or greater, with the greatest proportional increases observed in Bhutan, Nepal and Bangladesh. The highest numbers of new cases were reported from India (112,456 new cases, an increase of 21 per cent), Thailand (15,950, an increase of 6 per cent) and Bangladesh (13,516 new cases, a 53 per cent increase).

    The number of new weekly deaths in the region increased by 16 per cent as compared to the previous week, with over 350 new deaths reported.

    The highest numbers of new deaths were reported from India (200 new deaths, a 39 per cent increase), Thailand (108 new deaths, a decline of 14 per cent), and Indonesia (32 new deaths, an increase of 7 per cent).

    WHO Incident Manager COVID-19 Abdi Mahamud said that now is not the time to declare that the pandemic is over. “We’re still in the midst of the pandemic and the virus has a lot of force left. So whether it is the BA.4 or BA.5 or BA.2.75, the virus will continue. It does what it does good,”  he said adding that people and communities must continue to wear masks, avoid crowds and ensure that the most vulnerable and high-risk population is protected.

  • NTAGI members agree on reducing Covid booster dose gap to six months; discuss monkeypox

    By PTI

    NEW DELHI: Members of the government advisory panel NTAGI on Thursday agreed on reducing the gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months, official sources said.

    A recommendation for it will be made to the Health Ministry soon, they said.

    The NTAGI’s Standing Technical Sub-Committee (STSC), which met on Thursday, also reviewed the findings of a study by the Christian Medical College (CMC) in Vellore on the feasibility of allowing as a precaution dose a Covid vaccine different from the one used for primary vaccination.

    The panel members found a lack of uniformity in results upon mixing of jabs for booster shots and stated that no recommendation for it can be made as of now.

    The CMC study was on Covishield and Covaxin.

    The threat of monkeypox and the requirement of vaccination were also discussed in the meeting, the sources said.

    “However, the members were of the view that a strong surveillance is what is required as of now. No case of monkeypox has been detected in the country till now,” one of the sources told PTI.

    The panel also reviewed data on Covaxin and Corbevax vaccines for the 6-12 age group.

    “The members opined that data of Covid burden and mortality among children is not robust enough to take any decision to begin vaccination of those below 12 years,” the source stated.

    India’s drug regulator in April this year had granted emergency use authorisation for Biological E’s COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech’s Covaxin for children in the age group of six to 12 years.

    The STSC members were learnt to have also agreed on the administration of an additional third dose for renal transplant patients before the precaution dose.

    “In the meeting today, members also agreed on reducing the gap between the second and the precaution doses of COVID-19 vaccines from the current nine months to six months,” the source told PTI.

    Currently, all those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.

    The Union government last month allowed citizens and students travelling overseas to get the shot before the stipulated nine-month waiting period as required by the guidelines of the destination country.

  • Second Covishield dose can be given between 8-16 weeks after first: NTAGI

    The NTAGI has not yet suggested any change in the schedule of Bharat Biotech's Covaxin, whose second dose is administered 28 days after the first dose.

  • No need to vaccinate children against Covid-19 now, says advisory group; Omicron cases cross 200 in India

    By Online Desk

    NEW DELHI: The National Technical Advisory Group on Immunisation in India (NTAGI) member Dr Jayaprakash Muliyil has, for now, ruled out the need to vaccinate children against Covid-19.

    The panel has informed the Centre that the children are doing fine and there is no need to vaccinate them now.

    India has not witnessed a single death among children below 12 years of age due to Covid-19, said Muliyil, one of the country’s leading epidemiologists, news18.com reports.

    After an evaluation meeting held on December 8, NTAGI had said that many companies are still in the process of conducting scientific trials. Thus, no official dates have been announced to commence the vaccination drive for those below the age of 18 in the country.

    According to a last month’s report, over 100 countries around the world have extended their Covid-19 vaccination drives to children. France on Monday approved the Pfizer-BioNTech COVID-19 vaccine for all children aged 5-11

    Meanwhile, Delhi on Tuesday reported 24 new cases of Omicron variant of Covid-19. The number of Omicron cases in the country stood at 202 on Tuesday.